TABLE III.
Systemic therapy delivered in stage IIIB/IV non-small-cell lung cancer by histology and year
| Therapy type | Patients [n (%)] treated in | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| 2007 | 2011 | |||||
|
|
|
|||||
| Nonsquamous (n=277) | Squamous (n=84) | NOS (n=310) | Nonsquamous (n=426) | Squamous (n=115) | NOS (n=139) | |
| First line | 83 (30) | 18 (21) | 69 (22) | 137 (32) | 30 (26) | 30 (22) |
| Platinum doublet | 65 (78) | 17 (94) | 58 (84) | 73 (53) | 26 (87) | 21 (70) |
| Platinum–pemetrexed | 31 (23) | 4 (13) | ||||
| Single agent | 9 (11) | 1 (6) | 6 (9) | 8 (6) | 3 (10) | 2 (7) |
| EGFR TKI | 9 (11) | 5 (7) | 25 (18) | 1 (3) | 3 (10) | |
| Second line | 35 (42) | 10 (56) | 29 (42) | 86 (63) | 12 (40) | 19 (63) |
| Docetaxel | — | 1 (8) | — | |||
| Pemetrexed | 15 (43) | 3 (30) | 7 (24) | 23 (27) | — | 5 (26) |
| Maintenance | 5 | — | — | |||
| Second line | 18 | — | 5 | |||
| Erlotinib | 13 (37) | 4 (40) | 11 (38) | 48 (56) | 9 (75) | 11 (58) |
| Maintenance | 5 | 1 | 1 | |||
| Second line | 43 | 8 | 10 | |||
| Platinum doublet | 5 (14) | 7 (24) | 11 (13) | 1 (8) | 3 (16) | |
| Platinum–pemetrexed | 3 (3) | — | — | |||
| Other | 2 (6) | 3 (30) | 4 (14) | 1 (1) | 1 (8) | — |
| Third line | 14 (40) | 2 (20) | 15 (52) | 35 (41) | 4 (33) | 8 (42) |
| Docetaxel | 6 (17) | — | 1 (13) | |||
| Pemetrexed | 4 (29) | 3 (20) | 8 (23) | 1 (25) | 2 (25) | |
| Erlotinib | 9 (64) | 0 | 10 (67) | 15 (43) | 2 (50) | 5 (62) |
| Platinum doublet | 4 (11) | — | — | |||
| Platinum–pemetrexed | 1 (3) | — | — | |||
| Other | 1 (7) | 2 (100) | 2 (13) | 1 (3) | 1 (25) | |
| All lines | ||||||
| Pemetrexed | ||||||
| No | 64 (77) | 15 (83) | 59 (86) | 84 (61) | 29 (97) | 19 (63) |
| Yes | 19 (23) | 3 (17) | 10 (14) | 53 (39) | 1 (3) | 11 (37) |
| EGFR TKI | ||||||
| No | 53 (64) | 14 (78) | 46 (67) | 49 (36) | 12 (40) | 11 (37) |
| Yes | 30 (36) | 4 (22) | 23 (33) | 88 (64) | 18 (60) | 19 (63) |
nos = not otherwise specified; egfr tki = epidermal growth factor inhibitor tyrosine kinase inhibitor.